APA (7th ed.) Citation

R, S., JM, D. B., P, A., H, M., V, C., V, S., . . . M, I. (2022). Infigratinib in children with achondroplasia: The PROPEL and PROPEL 2 studies. Therapeutic advances in musculoskeletal disease, 14, 1759720X221084848. https://doi.org/10.1177/1759720X221084848

Chicago Style (17th ed.) Citation

R, Savarirayan, et al. "Infigratinib in Children with Achondroplasia: The PROPEL and PROPEL 2 Studies." Therapeutic Advances in Musculoskeletal Disease 14 (2022): 1759720X221084848. https://doi.org/10.1177/1759720X221084848.

MLA (9th ed.) Citation

R, Savarirayan, et al. "Infigratinib in Children with Achondroplasia: The PROPEL and PROPEL 2 Studies." Therapeutic Advances in Musculoskeletal Disease, vol. 14, 2022, p. 1759720X221084848, https://doi.org/10.1177/1759720X221084848.